Selective melanocortin MC 4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage

British Journal of Pharmacology

Volumn 150, Issue 5, 2007, Pages 595-603

  Giuliani, D ^a   Mioni, C ^a   Bazzani, C ^a   Zaffe, D ^a   Botticelli, A R ^b   Capolongo, S ^a   Sabba, A ^a   Galantucci, M ^a   Iannone, A ^a   Grieco, P ^c   Novellino, E ^c   Colombo, G ^d   Tomasi, A ^a   Catania, A ^d   Guarini, S ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Free radicals; Haemorrhagic shock; Melanocortin MC 4 receptors; Melanocortin peptides; Organ damage

Indexed keywords

ALPHA INTERMEDIN DERIVATIVE; FREE RADICAL; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; HS 024; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; PG 931; RO 27 3225; SODIUM CHLORIDE; UNCLASSIFIED DRUG; AC NLE C(ASP PRO D PHE ARG TRP LYS) PRO VAL NH2; AC-NLE-C(ASP-PRO-D-PHE-ARG-TRP-LYS)-PRO-VAL-NH2; ALPHA INTERMEDIN; CYCLOPEPTIDE; DRUG DERIVATIVE; MSH, 4 NLE 7 PHE ALPHA; MSH, 4-NLE-7-PHE-ALPHA-;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG SELECTIVITY; ELECTRON SPIN RESONANCE; FEMALE; GENERAL ANESTHESIA; HEART; HEMORRHAGIC SHOCK; HISTOLOGY; IMMUNOCYTOCHEMISTRY; KIDNEY; LIVER; LUNG; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY FUNCTION; SURVIVAL RATE; TISSUE INJURY; ANIMAL; BLOOD; BLOOD PRESSURE; BREATHING MECHANICS; DISEASE MODEL; DRUG POTENTIATION; HEART MUSCLE; HEART RATE; HOSPITALIZATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME; WISTAR RAT;

ALPHA-MSH; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICALS; HEART RATE; KIDNEY; LIVER; LUNG; MULTIPLE ORGAN FAILURE; MYOCARDIUM; PEPTIDES, CYCLIC; RATS; RATS, WISTAR; RECEPTOR, MELANOCORTIN, TYPE 4; RESPIRATORY MECHANICS; SEVERITY OF ILLNESS INDEX; SHOCK, HEMORRHAGIC; TIME FACTORS;

EID: 33847690196     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707115     Document Type: Article

References (61)

1. Altavilla D, Cainazzo MM, Squadrito F, Guarini S, Bertolini A, Bazzani C (1998). Tumour necrosis factor-α as a target of melanocortins in haemorrhagic shock, in the anaesthetized rat. Br J Pharmacol 124: 1587-1590.
2. Altavilla D, Guarini S, Bitto A, Mioni C, Giuliani D, Bigiani A et al. (2006). Activation of the cholinergic anti-inflammatory pathway reduces NF-κB activation, blunts TNF-α production, and protects against splanchnic artery occlusion shock. Shock 25: 500-506.
3. Banks WA, Kastin AJ (1995). Permeability of the blood-brain barrier to melanocortins. Peptides 16: 1157-1161.
4. Baue AE (1997). Multiple organ failure, multiple organ dysfunction syndrome and systemic inflammatory response syndrome. Why no magic bullets? Arch Surg 132: 703-707.
5. Bazzani C, Guarini S, Botticelli AR, Zaffe D, Tomasi A, Bini A et al. (2001). Protective effect of melanocortin peptides in rat myocardial ischemia. J Pharmacol Exp Ther 297: 1082-1087.
6. Benoit SC, Schwartz MW, Lachey JL, Hagan MM, Rushing PA, Blake KA et al. (2000). A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J Neurosci 20: 3442-3448.
7. Bertolini A, Guarini S, Ferrari W (1986a). Adrenal-independent, antishock effect of ACTH-(1-24) in rats. Eur J Pharmacol 122: 387-388.
8. Bertolini A, Guarini S, Rompianesi E, Ferrari W (1986b). α-MSH and other ACTH fragments improve cardiovascular function and survival in experimental hemorrhagic shock. Eur J Pharmacol 130: 19-26.
9. Bertuglia S, Giusti A (2004). Influence of ACTH-(1-24) and plasma hyperviscosity on free radical production and capillary perfusion after hemorrhagic shock. Microcirculation 11: 227-238.
10. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR et al. (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458-462.
11. Buettner GB (1987). Spin trapping: esr parameters of spin adducts. Free Radical Biol Med 3: 259-303.
12. Catania A, Cutuli M, Garofalo L, Airaghi L, Valenza F, Lipton JM et al. (2000). Plasma concentrations and anti-cytokine effects of α-melanocyte stimulating hormone in septic patients. Crit Care Med 28: 1403-1407.
13. Catania A, Gatti S, Colombo G, Lipton JM (2004). Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 56: 1-29.
14. Cockerill GW, Mcdonald MC, Mota-Filipe H, Cuzzocrea S, Miller NE, Thiemermann C (2001). High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J 15: 1941-1952.
15. Colombo G, Gatti S, Turcatti F, Sordi A, Fassati LR, Bonino F et al. (2005). Gene expression profiling reveals multiple protective influences of the peptide α-melanocyte-stimulating hormone in experimental heart transplantation. J Immunol 175: 3391-3401.
16. Cui X, Wu R, Zhou M, Dong W, Ulloa L, Yang H et al. (2005). Adrenomedullin and its binding protein attenuate the proinflammatory response after hemorrhage. Crit Care Med 33: 391-398.
17. Davies MJ, Gilbert BC, Haywood RM (1991). Radical-induced damage to proteins - ESR spin trapping studies. Free Radical Res Commun 15: 111-127.
18. Gatti S, Colombo G, Buffa R, Turcatti F, Carofalo L, Carboni N et al. (2002). α-Melanocyte-stimulating hormone protects the allograft in experimental heart transplantation. Transplantation 74: 1678-1684.
19. Getting SJ (2006). Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 111: 1-15.
20. Getting SJ, Christian HC, Lam CW, Gavins FN, Flower RJ, Schioth HB et al. (2003). Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides: studies in the recessive yellow (e/e) mouse suggest an important role for melocortin 3 receptor. J Immunol 170: 3323-3330.
21. Giordano FJ (2005). Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115: 500-508.
22. 7]α-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils. Eur J Pharmacol 538: 48-56.
23. Giuliani D, Mioni C, Altavilla D, Leone S, Bazzani C, Minutoli L et al. (2006b). Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology 147: 1126-1135.
24. Gobe G, Zhang XJ, Willgoss DA, Schoch E, Hogg NA, Endre ZH (2000). Relationship between expression of Bcl-2 genes and growth factors in ischemic acute renal failure in the rat. J Am Soc Nephrol 11: 454-467.
25. Grieco P, Balse-Srinivasan P, Han G, Weinberg D, Macneil T, Van Der Ploeg LHT et al. (2003). Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5. J Peptide Res 62: 199-206.
26. Grieco P, Lavecchia A, Cai M, Trivedi D, Weinberg D, Macnail T et al. (2002). Structure-activity studies of the melanocortin peptides: discovery of potent and selective antagonists at hMC3 and hMC4 receptors. J Med Chem 45: 5287-5294.
27. Guarini S, Altavilla D, Cainazzo MM, Giuliani D, Bigiani A, Marini H et al. (2003). Efferent vagal fibre stimulation blunts NF-κB activation and protects against hypovolemic hemorrhagic shock. Circulation 107: 1189-1194.
28. Guarini S, Bazzani C, Bertolini A (1997a). Resuscitating effect of melanocortin peptides after prolonged respiratory arrest. Br J Pharmacol 121: 1454-1460.
29. Guarini S, Bazzani C, Cainazzo MM, Mioni C, Ferrazza G, Vergoni AV et al. (1999). Evidence that melanocortin 4 receptor mediates hemorrhagic shock reversal caused by melanocortin peptides. J Pharmacol Exp Ther 291: 1023-1027.
30. Guarini S, Bazzani C, Mattera Ricigliano G, Bini A, Tomasi A, Bertolini A (1996). Influence of ACTH-(1-24) on free radical levels in the blood of haemorrhage-shocked rats: direct ex vivo detection by electron spin resonance spectrometry. Br J Pharmacol 119: 29-34.
31. Guarini S, Bini A, Bazzani C, Mattera Ricigliano G, Cainazzo MM, Tomasi A et al. (1997b). Adrenocorticotropin normalizes the blood levels of nitric oxide in hemorrhage-shocked rats. Eur J Pharmacol 336: 15-21.
32. Guarini S, Cainazzo MM, Giuliani D, Mioni C, Altavilla D, Marini H et al. (2004). Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway. Cardiovasc Res 63: 357-365.
33. 3 receptors are involved in the protective effect of melanocortins in myocardial ischaemia/reperfusion-induced arrhythmias. Naunyn-Schmiedeberg's Arch Pharmacol 366: 177-182.
34. Guarini S, Tagliavini S, Bazzani C, Ferrari W, Bertolini A (1990). Early treatment with ACTH-(1-24) in a rat model of hemorrhagic shock prolongs survival and extends the time-limit for blood reinfusion to be effective. Crit Care Med 18: 862-865.
35. Guarini S, Vergoni AV, Bertolini A (1987). Anti-shock effect of ACTH-(1-24): comparison between intracerebroventricular and intravenous route of administration. Pharmacol Res Commun 19: 255-260.
36. Horton JW, Borman KR (1987). Possible role of oxygen-derived free radicals in cardiocirculatory shock. Surg Gynecol Obstet 165: 293-300.
37. Kask A, Mutulis F, Muceniece R, Pähkla R, Mutule I, Wikberg JES et al. (1998). Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. Endocrinology 139: 5006-5014.
38. Krizbai IA, Lenzser G, Szatmari E, Farkas AE, Wilhelm I, Fekete Z et al. (2005). Blood-brain barrier changes during compensated and decompensated hemorrhagic shock. Shock 24: 428-433.
39. Le Tulzo Y, Shenkar R, Kaneko D, Moine P, Fantuzzi G, Dinarello CA et al. (1997). Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-kB regulation and cytokine expression. J Clin Invest 99: 1516-1524.
40. Ling MK, Hotta E, Kilianova Z, Haitina T, Ringholm A, Johansson L et al. (2004). The melanocortin receptor subtypes in chicken have high preference to ACTH-derived peptides. Br J Pharmacol 143: 626-637.
41. Magnoni S, Stocchetti N, Colombo G, Carlin A, Colombo A, Lipton JM et al. (2003). α-Melanocyte-stimulating hormone is decreased in plasma of patients with acute brain injury. J Neurotrauma 20: 251-260.
42. Mccord JM (1985). Oxygen-derived free radicals in post-ischemic tissue injury. New Engl J Med 312: 159-163.
43. Mcdonald MC, Mota-Filipe H, Paul A, Cuzzocrea S, Abdelrahman M, Harwood S et al. (2001). Calpain inhibitor I reduces the activation of nuclear factor-kB and organ injury/dysfunction in hemorrhagic shock. FASEB J 15: 171-186.
44. Mioni C, Bazzani C, Giuliani D, Altavilla D, Leone S, Ferrari A et al. (2005). Activation of an efferent cholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in rats. Crit Care Med 33: 2621-2628.
45. 3 receptors. Eur J Pharmacol 477: 227-234.
46. Mountjoy KG, Wu C-SJ, Dumont LM, Wild JM (2003). Melanocortin-4 receptor messenger ribonucleic acid expression in rat cardiorespiratory, musculoskeletal, and integumentary systems. Endocrinology 144: 5488-5496.
47. Noera G, Lamarra M, Guarini S, Bertolini A (2001). Survival rate after early treatment for acute type-A aortic dissection with ACTH-(1-24). Lancet 358: 469-470.
48. Pavlov VA, Tracey KJ (2005). The cholinergic anti-inflammatory pathway. Brain Behav Immunol 19: 493-499.
49. Redl H, Gasser H, Schlag G, Marzi I (1993). Involvement of oxygen radicals in shock related cell injury. Br Med Bull 49: 556-565.
50. Schlag G, Redl H, Hallström S (1991). The cell in shock: the origin of multiple organ failure. Resuscitation 21: 137-180.
51. Seekamp AJ, Jochum M, Ziegler M, Micheal M, Gerd R (1998). Cytokine and adhesion molecules in elective and accidental trauma-related ischaemia/reperfusion. J Trauma 44: 874-882.
52. Simons RK, Hoyt DB, Winchell RJ, Rose RM, Holbrook T (1996). Elevated selectin levels after severe trauma: a marker for sepsis and organ failure and a potential target for immunomodulatory therapy. J Trauma 41: 653-662.
53. Squadrito F, Guarini S, Altavilla D, Squadrito G, Campo GM, Arlotta M et al. (1999). Adrenocorticotropin reverses vascular dysfunction and protects against splanchnic artery occlusion shock. Br J Pharmacol 128: 816-822.
54. Tatro JB (2000). Melanocortin receptor expression and function in the nervous system. In: Cone RD (ed). The Melanocortin Receptors. Humana Press: Totowa, pp. 173-207.
55. Tortolani AJ, Powell SR, Misik V, Weglicki WB, Pogo GJ, Kramer JH (1993). Detection of alkoxyl and carbon-centered free radicals in coronary sinus blood from patients undergoing elective cardioplegia. Free Radical Biol Med 14: 421-426.
56. Tracey KJ (2002). The inflammatory reflex. Nature 420: 853-859.
57. Vecsernyes M, Juhasz B, Der P, Kocsan R, Feher P, Bacskay I et al. (2003). The administration of α-melanocyte-stimulating hormone protects the ischemic/reperfused myocardium. Eur J Pharmacol 470: 177-183.
58. Victor VM, Rocha M, Esplugues JV, De La Fuente M (2005). Role of free radicals in sepsis: antioxidant therapy. Curr Pharm Des 11: 3141-3158.
59. Wheeler AP, Bernard GR (1999). Treating patients with severe sepsis. N Engl J Med 340: 207-214.
60. Wikberg JES, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C et al. (2000). New aspects on the melanocortins and their receptors. Pharmacol Res 42: 393-420.
61. Wilson JF (1988). Low permeability of the blood-brain-barrier to nanomolar concentrations of immunoreactive α-melanotropin. Psychopharmacology 96: 262-266.